Statin use and risk of pancreatic cancer: A meta-analysis

Cancer Causes and Control

Volumn 23, Issue 7, 2012, Pages 1099-1111

  Cui, Xiaobing ^a   Xie, Yue ^a   Chen, Min ^a   Li, Jun ^a   Liao, Xiaoming ^a   Shen, Jian ^b   Shi, Meng ^a   Li, Wenjing ^a   Zheng, Haoxuan ^a   Jiang, Bo ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Meta analysis; Pancreatic cancer; Prevention; Risk; Statin

Indexed keywords

ATORVASTATIN; CERIVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ARTICLE; CANCER RISK; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; DISEASE ASSOCIATION; DRUG SAFETY; DRUG USE; FOLLOW UP; HUMAN; ISCHEMIC HEART DISEASE; LIPOPHILICITY; META ANALYSIS; PANCREAS CANCER; PRIORITY JOURNAL; PUBLISHING; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK FACTOR; SILENT MYOCARDIAL ISCHEMIA; STABLE ANGINA PECTORIS; SYSTEMATIC REVIEW; TREATMENT DURATION; UNSTABLE ANGINA PECTORIS;

CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; COHORT STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PANCREATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; RISK FACTORS;

EID: 84862492891     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-012-9979-9     Document Type: Article

References (53)

1. Siegel R, Ward E, Brawley O, Jemal A (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61(4): 212-236. doi:10.3322/caac.20121
2. Hidalgo M (2010) Pancreatic cancer. N Engl J Med 362(17):1605-1617. doi:10.1056/NEJMra0901557
3. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366(9493):1267-1278. doi: 10.1016/S0140-6736(05)67394-1
4. Newman TB, Hulley SB (1996) Carcinogenicity of lipid-lowering drugs. JAMA 275(1):55-60 (Pubitemid 26004257)
5. Chan KK, Oza AM, Siu LL (2003) The statins as anticancer agents. Clin Cancer Res 9(1):10-19 (Pubitemid 36109711)
6. Vaklavas C, Chatzizisis YS, Tsimberidou AM (2011) Common cardiovascular medications in cancer therapeutics. Pharmacol Ther 130(2):177-190. doi:10.1016/j.pharmthera.2011.01.009
7. Sumi S, Beauchamp RD, Townsend CM Jr, Uchida T, Murakami M, Rajaraman S, Ishizuka J, Thompson JC (1992) Inhibition of pancreatic adenocarcinoma cell growth by lovastatin. Gastroenterology 103(3):982-989
8. Sumi S, Beauchamp RD, Townsend CM Jr, Pour PM, Ishizuka J, Thompson JC (1994) Lovastatin inhibits pancreatic cancer growth regardless of RAS mutation. Pancreas 9(5):657-661 (Pubitemid 24276959)
9. Kusama T, Mukai M, Iwasaki T, Tatsuta M, Matsumoto Y, Akedo H, Nakamura H (2001) Inhibition of epidermal growth factor- induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors. Cancer Res 61(12):4885-4891 (Pubitemid 32691906)
10. Kusama T, Mukai M, Iwasaki T, Tatsuta M, Matsumoto Y, Akedo H, Inoue M, Nakamura H (2002) 3-hydroxy-3-methylglutarylcoenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis. Gastroenterology 122(2):308-317 (Pubitemid 34116983)
11. Gbelcova H, Lenicek M, Zelenka J, Knejzlik Z, Dvorakova G, Zadinova M, Pouckova P, Kudla M, Balaz P, Ruml T, Vitek L (2008) Differences in antitumor effects of various statins on human pancreatic cancer. Int J Cancer 122(6):1214-1221. doi: 10.1002/ijc.23242 (Pubitemid 351287219)
12. Khurana V, Sheth A, Caldito G, Barkin JS (2007) Statins reduce the risk of pancreatic cancer in humans-a case-control study of half a million veterans. Pancreas 34(2):260-265. doi:10.1097/MPA.0b013e318030e963 (Pubitemid 46294804)
13. Kaye JA, Jick H (2004) Statin use and cancer risk in the general practice research database.Br J Cancer 90(3):635-637. doi:10.1038/sj.bjc.6601566 (Pubitemid 38297203)
14. Bradley MC, Hughes CM, Cantwell MM, Murray LJ (2010) Statins and pancreatic cancer risk: a nested case-control study. Cancer Causes Control 21(12):2093-2100. doi:10.1007/s10552-010-9628-0
15. Chiu H-F, Chang C-C, Ho S-C, Wu T-N, Yang C-Y (2011) Statin use and the risk of pancreatic cancer a population-based casecontrol study. Pancreas 40(5):669-672. doi:10.1097/MPA.0b013e31821fd5cd
16. Friedman GD, Flick ED, Udaltsova N, Chan J, Quesenberry CP Jr, Habel LA (2008) Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf 17(1):27-36. doi:10.1002/pds.1507 (Pubitemid 351166615)
17. Bonovas S, Filioussi K, Sitaras NM (2008) Statins are not associated with a reduced risk of pancreatic cancer at the population level, when taken at low doses for managing hypercholesterolemia: evidence from a meta-analysis of 12 studies. Am J Gastroenterol 103(10):2646-2651. doi:10.1111/j.1572-0241.2008. 02051.x
18. Vitek L (2009) Statins and pancreatic cancer: are all statins the same? Am J Gastroenterol 104(2):525. doi:10.1038/ajg.2008.103 (author reply 525)
19. Duncan RE, El-Sohemy A, Archer MC (2005) Statins and cancer development. Cancer Epidemiol Biomarkers Prev 14(8): 1897-1898. doi:10.1158/1055-9965.EPI-05- 0027 (Pubitemid 41161197)
20. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA 283(15):2008-2012 (Pubitemid 30214957)
21. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535. doi:10.1136/bmj.b2535
22. Lovastatin Study Groups I Through IV (1993) Lovastatin 5-year safety and efficacy study. Arch Intern Med 153(9):1079-1087
23. Olsen JH, Johansen C, Sorensen HT, McLaughlin JK, Mellemkjaer L, Steffensen FH, Fraumeni JF Jr (1999) Lipid-lowering medication and risk of cancer. J Clin Epidemiol 52(2):167-169 (Pubitemid 29118368)
24. Higgins JP, Green S (2011) Cochrane handbook for systematic reviews of interventions. http://www.cochrane-handbook.org/
25. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P (2012) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical- epidemiology/oxford.asp
26. Bardou M, Barkun A, Martel M (2010) Effect of statin therapy on colorectal cancer. Gut 59(11):1572-1585. doi:10.1136/gut.2009.190900
27. Midgette AS, Wong JB, Beshansky JR, Porath A, Fleming C, Pauker SG (1994) Cost-effectiveness of streptokinase for acute myocardial infarction: a combined meta-analysis and decision analysis of the effects of infarct location and of likelihood of infarction. Med Decis Making 14(2):108-117 (Pubitemid 24116539)
28. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557-560. doi:10.1136/bmj.327.7414. 557 (Pubitemid 37088507)
29. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109): 629-634 (Pubitemid 27387172)
30. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50(4): 1088-1101
31. Clearfield M, Downs JR, Weis S, Whitney EJ, Kruyer W, Shapiro DR, Stein EA, Langendorfer A, Beere PA, Gotto AM (2001) Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/ TexCAPS): efficacy and tolerability of long-term treatment with lovastatin in women. J Women's Health Gender Based Med 10(10):971-981. doi:10.1089/152460901317193549 (Pubitemid 34065628)
32. Serruys PW, de Feyter P, Macaya C, Kokott N, Puel J, Vrolix M, Branzi A, Bertolami MC, Jackson G, Strauss B, Meier B (2002) Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 287(24):3215-3222 (Pubitemid 34686102)
33. Strandberg TE, Pyorala K, Cook TJ, Wilhelmsen L, Faergeman O, Thorgeirsson G, Pederson TR, Kjekshus J (2004) Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 364(9436): 771-777. doi:10.1016/s0140-6736(04)16936-5 (Pubitemid 39165096)
34. Jacobs EJ, Newton CC, Thun MJ, Gapstur SM (2011) Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort. Cancer Res 71(5):1763-1771. doi:10.1158/0008-5472.can-10-2953
35. Marelli C, Gunnarsson C, Ross S, Haas S, Stroup DF, Cload P, Clopton P, DeMaria AN (2011) Statins and risk of cancer a retrospective cohort analysis of 45,857 matched pairs from an electronic medical records database of 11 million adult Americans. J Am Coll Cardiol 58(5):530-537. doi:10.1016/j.jacc.2011.04.015
36. Haukka J, Sankila R, Klaukka T, Lonnqvist J, Niskanen L, Tanskanen A, Wahlbeck K, Tiihonen J (2010) Incidence of cancer and statin usage - record linkage study. Int J Cancer 126(1):279-284. doi:10.1002/ijc.24536
37. Sato S, Ajiki W, Kobayashi T, Awata N (2006) Pravastatin use and the five-year incidence of cancer in coronary heart disease patients: from the prevention of coronary sclerosis study. J Epidemiol 16(5):201-206 (Pubitemid 44574685)
38. Graaf MR, Beiderbeck AB, Egberts ACG, Richel DJ, Guchelaar H-J (2004) The risk of cancer in users of statins. J Clin Oncol 22(12):2388-2394. doi:10.1200/jco.2004.02.027 (Pubitemid 41115396)
39. Coogan PF, Rosenberg L, Strom BL (2007) Statin use and the risk of 10 cancers. Epidemiology 18(2):213-219. doi:10.1097/01.ede.0000254694.03027.a1
40. Pugh TE, Little MW, Carey FJ, Robinson RJ, Clark A, Metcalfe M, Ndokera R, Ing H, Dennison A, Hart A (2011) Aspirin, NSAIDS, calcium-channel blockers and statins in the aetiology of pancreatic cancer: preliminary results from a case-control study in two centres in the UK. Gut 60(Suppl 1):A81. doi:10.1136/gut.2011.239301.166
41. Dorais M TR, Rakel A, Lelorrier J, Panzini B (2007) Statins, nsaids and pancreatic cancer. Paper presented at the 4th Canadian therapeutics congress, Halifax, Nova Scotia, 10 May 2007. http://www.cjcp.ca/pubmed.php?articleId=113
42. Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F (1999) New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 84(3):413-428
43. Moorman PG, Hamilton RJ (2007) Statins and cancer risk: what do we know and where do we go from here? Epidemiology 18(2):194-196. doi:10.1097/01.ede. 0000254699.31405.e2
44. Brookhart MA, Patrick AR, Dormuth C, Avorn J, Shrank W, Cadarette SM, Solomon DH (2007) Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. Am J Epidemiol 166(3):348-354. doi: 10.1093/aje/kwm070 (Pubitemid 47216808)
45. Boudreau DM, Yu O, Johnson J (2010) Statin use and cancer risk: a comprehensive review. Expert Opin Drug Saf 9(4):603-621. doi:10.1517/ 14740331003662620
46. Dale KM, Coleman CI, Henyan NN, Kluger J, White CM (2006) Statins and cancer risk: a meta-analysis. JAMA 295(1):74-80. doi:10.1001/jama.295.1.74 (Pubitemid 43042692)
47. Kuoppala J, Lamminpaa A, Pukkala E (2008) Statins and cancer: a systematic review and meta-analysis. Eur J Cancer 44(15):2122-2132. doi:10.1016/j.ejca.2008.06.025
48. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R (2010) Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376(9753):1670-1681. doi:10.1016/s0140-6736(10)61350-5
49. Shimoyama S (2011) Statins are logical candidates for overcoming limitations of targeting therapies on malignancy: their potential application to gastrointestinal cancers. Cancer Chemother Pharmacol 67(4):729-739. doi:10.1007/s00280-011-1583-2
50. Alsheikh-Ali AA, Karas RH (2009) The relationship of statins to rhabdomyolysis, malignancy, and hepatic toxicity: evidence from clinical trials. Curr Atheroscler Rep 11(2):100-104
51. Bocci G, Fioravanti A, Orlandi P, Bernardini N, Collecchi P, Del Tacca M, Danesi R (2005) Fluvastatin synergistically enhances the antiproliferative effect of gemcitabine in human pancreatic cancer MIAPaCa-2 cells. Br J Cancer 93(3):319-330. doi: 10.1038/sj.bjc.6602720 (Pubitemid 43080034)
52. Dimitroulakos J, Lorimer IA, Goss G (2006) Strategies to enhance epidermal growth factor inhibition: targeting the mevalonate pathway. Clin Cancer Res 12(14 Pt 2):4426s-4431s. doi: 10.1158/1078-0432.CCR-06-0089 (Pubitemid 44197193)
53. Trial of Simvastatin and Gemcitabine in Pancreatic Cancer Patients (2012) http://clinicaltrials.gov/ct2/show/NCT00944463